# TScan Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/TScan Therapeutics, Inc.). ## Overview TScan Therapeutics is a U.S.-based clinical-stage biotechnology company developing T cell receptor-engineered T cell, or TCR-T, therapies for cancer. Its platform centers on an ImmunoBank of therapeutic TCRs and a pipeline of product candidates for hematologic malignancies and solid tumors, with research, manufacturing, and development activities based in the United States. ## Products & services • TCR-T therapy product candidates • ImmunoBank of therapeutic TCRs • TSC-101 lead clinical program • TSC-102-A01 and TSC-102-A03 heme programs • TCR discovery and antigen identification collaborations - **Clinical-stage TCR-T therapies** (0%) — Engineered T cell therapies designed to recognize cancer targets through specific T cell receptors. - **ImmunoBank platform** (0%) — A proprietary repository of therapeutic TCRs used to build and expand the pipeline. - **Research collaborations and licenses** (100%) — Partnered discovery and licensing arrangements that generate collaboration revenue. - TCR-T therapy product candidates - ImmunoBank of therapeutic TCRs - TSC-101 lead clinical program - TSC-102-A01 and TSC-102-A03 heme programs - TCR discovery and antigen identification collaborations ## Customers TScan’s direct customers are primarily pharmaceutical and biotechnology partners that license or collaborate on TCR discovery and antigen identification programs. Its eventual end users are cancer patients treated through hospitals and oncology centers if product candidates reach commercialization. The company’s current business model is therefore split between partner-funded research relationships and a clinical development pipeline aimed at future therapeutic use. - **Pharmaceutical collaboration partners** (primary) — Companies such as Amgen that fund research, receive data, and retain commercialization rights in partnered programs. - **Biotechnology research partners** (secondary) — Smaller or specialized biotech firms that may license TCR discovery capabilities or collaborate on antigen identification. - **Cancer patients** (primary) — Patients with hematologic or solid tumor cancers who would receive TCR-T therapies in clinical trials or after approval. - **Hospitals and oncology treatment centers** (secondary) — Clinical sites that enroll patients, administer cell therapy products, and support trial logistics. - Pharma partners seeking TCR discovery and antigen mapping - Biotech collaborators funding research and licensing programs - Oncology patients in future clinical and commercial use - Hospitals and cancer centers administering cell therapies - Regulatory stakeholders influencing trial design and approval ## Geography TScan is headquartered and operates primarily in the United States, where its corporate, research, and manufacturing activities are concentrated. Its manufacturing facility is in Waltham, Massachusetts, and its collaboration and clinical development work is also U.S.-based. The company’s commercial exposure is currently limited, but future expansion could extend beyond the U.S. if product candidates are approved or partnered internationally. - Headquartered in the United States - Manufacturing facility in Waltham, Massachusetts - Clinical development and research are U.S.-based - Current revenue is from U.S.-based collaboration activity - Future commercialization could expand internationally ## Strategy TScan’s strategy is to build a differentiated TCR-T pipeline using its ImmunoBank platform and to advance lead programs through clinical development. A key priority is internal manufacturing control, which supports process consistency, trial supply, and eventual commercial readiness. The company is also using collaborations and licensing to support research while it expands into additional hematologic and solid tumor targets. - **Advance TSC-101 and next heme programs** (short-term) — Clinical proof-of-concept is needed to validate the platform and support later-stage development. - **Expand the ImmunoBank platform** (medium-term) — A broader TCR library increases the number of target/HLA combinations the company can pursue. - **Strengthen manufacturing and process readiness** (medium-term) — Cell therapy development depends on reproducible, scalable, and controlled manufacturing. - Advance TCR-T candidates through Phase 1 and registrational studies - Expand the ImmunoBank with new therapeutic TCRs and targets - Use internal manufacturing to improve control and trial readiness - Develop commercial-ready processes for future scale-up - Pursue collaborations and licenses to support research funding ## Risks TScan faces the typical risks of a clinical-stage cell therapy company: uncertain clinical outcomes, regulatory review risk, and the need for substantial capital before any product revenue. It also competes in a crowded TCR and broader engineered T-cell market, where safety concerns, manufacturing complexity, and physician adoption can materially affect development and commercialization. - **Clinical development failure** [high] — TCR-T candidates may not demonstrate sufficient safety or efficacy in trials. - **Regulatory and safety scrutiny** [high] — The FDA may require additional monitoring, labeling, or trial changes for engineered T-cell products. - **Financing dependence** [high] — The company has no approved therapies and must fund development through external capital and collaborations. - **Competitive pressure** [medium] — Multiple companies are developing TCR-based and other cell therapies for similar cancer indications. - **Manufacturing complexity** [medium] — Cell therapies require controlled, reproducible manufacturing and supply chain reliability. - Clinical trials may fail to show safety or efficacy - Regulatory delays could slow or block product development - Additional capital may be needed before commercialization - Competition is intense across TCR, CAR-T, TIL, and NK therapies - Cell therapy safety events can hurt perception of the whole field ## Accounting TScan’s most important accounting issue is revenue recognition for collaboration and license agreements, which can require judgment on performance obligations and timing of recognition. As a clinical-stage biotech, it also relies heavily on estimates for research and development accruals, stock-based compensation, and the valuation of capital raises and debt-related costs. Because it has no product sales, collaboration revenue timing and development expense accruals can materially affect reported results from quarter to quarter. - **Collaboration revenue recognition** — Affects reported revenue timing and comparability across quarters - **Research and development accruals** — Can shift operating expense recognition between periods - **Stock-based compensation** — Affects operating loss and diluted share calculations - **Debt issuance and financing costs** — Influences interest expense and balance sheet presentation - Collaboration revenue is recognized under contract accounting judgments - Performance obligations affect timing of Amgen-related revenue - R&D accruals depend on trial and vendor cost estimates - Stock-based compensation is material for a development-stage biotech - No product sales means reported results are driven by non-product revenue --- *Last updated: 2026-04-29T05:02:41.725136+00:00*